- Home
- RNGT vs AARD Comparison
RNGT vs AARD Comparison
Compare RNGT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.37
Company Overview
Basic Information| Metric | RNGT | AARD |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.6M | 281.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RNGT | AARD |
|---|---|---|
| Price | $9.99 | $5.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 48.6K | ★ 83.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.93 | $4.88 |
| 52 Week High | $10.05 | $17.94 |
Technical Indicators
Market Signals| Indicator | RNGT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 17.22 |
| Support Level | $9.95 | N/A |
| Resistance Level | N/A | $15.88 |
| Average True Range (ATR) | 0.03 | 0.59 |
| MACD | -0.00 | -0.42 |
| Stochastic Oscillator | 40.00 | 1.40 |
Price Performance
Historical Comparison RNGT
AARD
About RNGT Range Capital Acquisition Corp II Class A Ordinary Shares
Range Capital Acquisition Corp II is a blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.